Compare NAZ & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAZ | LENZ |
|---|---|---|
| Founded | 1992 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.0M | 155.5M |
| IPO Year | 1995 | 2021 |
| Metric | NAZ | LENZ |
|---|---|---|
| Price | $12.05 | $5.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.00 |
| AVG Volume (30 Days) | 14.1K | ★ 674.6K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,088,000.00 |
| Revenue This Year | N/A | $50.42 |
| Revenue Next Year | N/A | $197.16 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.63 | $4.54 |
| 52 Week High | $13.42 | $50.19 |
| Indicator | NAZ | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 33.48 | 65.46 |
| Support Level | $11.98 | $4.59 |
| Resistance Level | $12.11 | $6.18 |
| Average True Range (ATR) | 0.13 | 0.27 |
| MACD | -0.02 | 0.14 |
| Stochastic Oscillator | 9.52 | 89.46 |
Nuveen Arizona Quality Municipal Income Fund is a closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.